Journal of Clinical Medicine Research

Objective: To evaluate the impact of clinical pharmacist interventions on the treatment efficacy and cost-effectiveness of high-cost ratio cases (unspecified bacterial pneumonia) in ICU wards under the Diagnosis-Intervention Packet (DIP) policy, and to provide references for the transformation plan of clinical pharmacist roles under the DIP policy. Methods: For the disease "unspecified bacterial pneumonia" (ICD-10 code: J15.9) with a high proportion of high-cost ratio cases in our ICU, interventions including developing clinical pharmacy pathways, conducting medical insurance pharmacy rounds, and reviewing excess disease group medical orders were implemented. Clinical efficacy and the proportion of high-cost cases before and after the intervention were compared. Cost-effectiveness analysis was used to evaluate the economic impact of the intervention. Results: There was no statistically significant difference in clinical efficacy before and after the intervention. However, the proportion of high-cost cases decreased significantly (from 60% to 23.3%), and the post-intervention cost-effectiveness ratio (174.09 CNY per 1% efficacy) was lower than the pre-intervention ratio (205.76 CNY per 1% efficacy). Conclusion: Clinical pharmacist interventions did not significantly alter clinical outcomes for the high-cost disease group but demonstrated clear economic advantages by reducing costs while maintaining efficacy. This highlights the potential of clinical pharmacists in optimizing cost control under the DIP policy.